Cargando…

Preclinical Efficacy Comparison of Cyclosporine Ophthalmic Solution 0.09% vs Cyclosporine Ophthalmic Emulsion 0.05% vs Ciclosporin Ophthalmic Emulsion 0.1% in a NOD Mouse Model of Dry Eye Disease

INTRODUCTION: Cyclosporine ophthalmic solution 0.09% (CsA 0.09% sol) is approved to increase tear production in patients with keratoconjunctivitis sicca. This study evaluated the efficacy of CsA 0.09% sol vs cyclosporine ophthalmic emulsion 0.05% (CsA 0.05% eml) vs ciclosporin ophthalmic emulsion 0....

Descripción completa

Detalles Bibliográficos
Autores principales:	Burade, Vinod, Zalawadia, Rishit, Patel, Alpesh, Ogundele, Abayomi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7518773/ https://www.ncbi.nlm.nih.gov/pubmed/33061257 http://dx.doi.org/10.2147/OPTH.S259331

Ejemplares similares

Patient and physician perspectives on the use of cyclosporine ophthalmic emulsion 0.05% for the management of chronic dry eye
por: Deveney, Tatiana, et al.
Publicado: (2018)

Real-World Treatment Patterns Of Cyclosporine Ophthalmic Emulsion And Lifitegrast Ophthalmic Solution Among Patients With Dry Eye
por: White, Darrell E, et al.
Publicado: (2019)

Cyclosporine 0.05% Ophthalmic Emulsion for Dry Eye in Korea: A Prospective, Multicenter, Open-Label, Surveillance Study
por: Byun, Yong-Soo, et al.
Publicado: (2011)

Dry Eye Treatment with Topical Cyclosporine 0.1% in Chondroitin Sulfate Ophthalmic Emulsion
por: Matossian, Cynthia, et al.
Publicado: (2021)

PERSIST: Physician’s Evaluation of Restasis(®) Satisfaction in Second Trial of topical cyclosporine ophthalmic emulsion 0.05% for dry eye: a retrospective review
por: Mah, Francis, et al.
Publicado: (2012)

Clinical utility of cyclosporine (CsA) ophthalmic emulsion 0.05% for symptomatic relief in people with chronic dry eye: a review of the literature
por: Rhee, Michelle K, et al.
Publicado: (2017)

Efficacy of Topical Cyclosporine Nanoemulsion 0.05% Compared with Topical Cyclosporine Emulsion 0.05% and Diquafosol 3% in Dry Eye
por: Park, Chang Hyun, et al.
Publicado: (2019)

The IMPACT study: a prospective evaluation of the effects of cyclosporine ophthalmic emulsion 0.05% on ocular surface staining and visual performance in patients with dry eye
por: Stonecipher, Karl G, et al.
Publicado: (2016)

Comparative analysis of 0.1% cyclosporin A cationic emulsion and 0.05% cyclosporin A emulsion in murine dry eye cases with different severities
por: Jin, Rujun, et al.
Publicado: (2021)

Dose uniformity of topical corticosteroid preparations: difluprednate ophthalmic emulsion 0.05% versus branded and generic prednisolone acetate ophthalmic suspension 1%
por: Stringer, William, et al.
Publicado: (2010)

Real-world treatment patterns of OTX-101 ophthalmic solution, cyclosporine ophthalmic emulsion, and lifitegrast ophthalmic solution in patients with dry eye disease: a retrospective analysis
por: Karpecki, Paul, et al.
Publicado: (2023)

Evaluation of analgesic efficacy of bromfenac sodium ophthalmic solution 0.09% versus ketorolac tromethamine ophthalmic solution 0.5% following LASEK or Epi-LASIK
por: Wang, Xiao Jing, et al.
Publicado: (2011)

Efficacy and safety of 0.05% micellar nano-particulate (MNP) cyclosporine ophthalmic emulsion in the treatment of moderate-to-severe keratoconjunctivitis sicca: a 12-week, multicenter, randomized, active-controlled trial
por: Rao, A Tarakeswara, et al.
Publicado: (2023)

Health claims database study of cyclosporine ophthalmic emulsion treatment patterns in dry eye patients
por: Stonecipher, Karl G, et al.
Publicado: (2013)

A Prospective Study of Cyclosporine A 0.1% Combined with Loteprednol 0.2% vs Cyclosporine A 0.05% Alone in the Treatment of Dry Eye
por: Hovanesian, John, et al.
Publicado: (2023)

Difluprednate ophthalmic emulsion 0.05% (Durezol(®)) administered two times daily for managing ocular inflammation and pain following cataract surgery
por: Smith, Stephen, et al.
Publicado: (2010)

Localized alopecia and suppression of hypothalamic-pituitary-adrenal (HPA) axis in dogs following treatment with difluprednate 0.05% ophthalmic emulsion (Durezol®)
por: Quantz, Katelin, et al.
Publicado: (2021)

Cyclosporine A (0.05%) Ophthalmic Gel in the Treatment of Dry Eye Disease: A Multicenter, Randomized, Double-Masked, Phase III, COSMO Trial
por: Peng, Wenyan, et al.
Publicado: (2022)

Efficacy and safety of 0.05% cyclosporine ophthalmic emulsion in treatment of Chinese patients with moderate to severe dry eye disease: A 12-week, multicenter, randomized, double-masked, placebo-controlled phase III clinical study
por: Chen, Di, et al.
Publicado: (2019)

In Vivo Pharmacokinetics of Bromfenac Ophthalmic Solution 0.075%, Bromfenac Ophthalmic Solution 0.07%, and Nepafenac/Amfenac Ophthalmic Suspension 0.3% in Rabbits
por: Sheppard, John D., et al.
Publicado: (2018)

Topical cyclosporine A cationic ophthalmic emulsion in paediatric vernal keratoconjunctivitis: pooled analysis of randomised NOVATIVE and VEKTIS trials
por: Leonardi, Andrea, et al.
Publicado: (2022)

Topical Ophthalmic Cyclosporine in the Treatment of Toxic Epidermal Necrolysis
por: Onaran, Zafer, et al.
Publicado: (2011)

Cyclosporine-Associated Leukoencephalopathy in a Case of Sympathetic Ophthalmitis
por: Tagami, Mizuki, et al.
Publicado: (2016)

The role of difluprednate ophthalmic emulsion in clinical practice
por: Jamal, Karim N, et al.
Publicado: (2009)

Efficacy and safety of topical cyclosporine 0.1% in moderate-to-severe dry eye disease refractory to topical cyclosporine 0.05% regimen
por: Chan, Yuan-Hsi, et al.
Publicado: (2023)

In vivo comparative study of ocular vasodilation, a relative indicator of hyperemia, in guinea pigs following treatment with bimatoprost ophthalmic solutions 0.01% and 0.03%
por: Ogundele, Abayomi B, et al.
Publicado: (2010)

The effect of topical 0.05% cyclosporine on recurrence following pterygium surgery
por: Turan-Vural, Ece, et al.
Publicado: (2011)

Besifloxacin Ophthalmic Suspension 0.6% Compared with Gatifloxacin Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis in Neonates
por: Sanfilippo, Christine M., et al.
Publicado: (2017)

The Effect of Topical Cyclosporine 0.05% on Dry Eye after Cataract Surgery
por: Chung, Yeon Woong, et al.
Publicado: (2013)

The Effect of Topical 0.05% Cyclosporine in the Prevention of Recurrence Following Pterygium Surgery
por: Karadag, Ayse Sevgi, et al.
Publicado: (2021)

Practical guidance for the use of cyclosporine ophthalmic solutions in the management of dry eye disease
por: de Oliveira, Rodrigo Carlos, et al.
Publicado: (2019)

Comparison of Drug Concentrations in Human Aqueous Humor after the Administration of 0.3% Gatifloxacin Ophthalmic Gel, 0.3% Gatifloxacin and 0.5% Levofloxacin Ophthalmic Solutions
por: Ding, Wenting, et al.
Publicado: (2015)

Lotilaner Ophthalmic Solution 0.25%: First Approval
por: Syed, Yahiya Y.
Publicado: (2023)

A Randomized Multicenter Study Comparing 0.1%, 0.15%, and 0.3% Sodium Hyaluronate with 0.05% Cyclosporine in the Treatment of Dry Eye
por: Park, Yuli, et al.
Publicado: (2017)

Stability, safety, and transcorneal mechanistic studies of ophthalmic lyophilized cyclosporine-loaded polymeric micelles
por: Shen, Yan, et al.
Publicado: (2018)

Correction to: Lotilaner Ophthalmic Solution 0.25%: First Approval
por: Syed, Yahiya Y.
Publicado: (2023)

Effect of Cyclosporine 0.09% Treatment on Accuracy of Preoperative Biometry and Higher Order Aberrations in Dry Eye Patients Undergoing Cataract Surgery
por: Hovanesian, John A, et al.
Publicado: (2021)

Cyclosporine a 0.05% eye drops for the treatment of subepithelial infiltrates after epidemic keratoconjunctivitis
por: Okumus, Seydi, et al.
Publicado: (2012)

Cyclosporine (0.05%) Combined with Diclofenac Sodium Eye Drops for the Treatment of Dry Eye Disease
por: Bai, Run, et al.
Publicado: (2022)

Dose Uniformity of Loteprednol Etabonate (Submicron) Ophthalmic Gel 0.38% Compared with Prednisolone Acetate Ophthalmic Suspension 1%
por: Marlowe, Zora T., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ig32gngqgvf9e6dkj1untqcnpa